Navigation Links
Nanomedical Diagnostics Launches New Biosensor for Label-free Kinetic Binding Analysis of Proteins
Date:7/18/2017

Nanomedical Diagnostics, a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of a new NTA biosensor chip for use with its label-free Agile R100 assay system. The new biosensor chip enables researchers to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably.

“Recombinant proteins are an essential part of many drug discovery programs, and they are often expressed with His-tags,” says Nanomedical Diagnostics CEO, Ross Bundy. “Prior methods for characterizing proteins involve many steps that make the process long, prone to error, and require specialist expertise. The new NTA Biosensor Chip combined with the breakthrough Agile R100 personal assay system decreases the steps needed to gather label-free kinetic binding data, which reduces variability and time to results. It simplifies the workflow so that anyone who can run an ELISA can run an Agile R100 assay with an NTA biosensor, which makes this information-rich, reliable data accessible to all researchers.”

Nitrilotriacetic acid (NTA) is pre-functionalized on the biosensor surface, enabling fast immobilization of His-tagged molecules. Each chip can provide up to 10 measurements, enabling an entire dose-response curve or replicate data to be run on one chip. Researchers can control the orientation of His-tagged proteins on the sensor surface and easily release them for chip reuse using standard NTA release protocol. Agile R100’s single-sample format brings the sample directly to the sensor surface, which means data can be gathered using a miniscule amount of material. This reduces the amount of protein synthesis required, increasing cost- efficiency. Agile R100 NTA biosensors can detect directly in complex solutions such as DMSO, cell and tissue lysate, and cell growth supernatant, drastically reducing sample prep time.

“The personal assay system Agile R100 lets scientists characterize compounds easily and affordably,” continues Mr. Bundy. “All Agile biosensors can sense in complex solutions with just a 10 µL drop of sample, and the launch of the NTA biosensor now provides additional chemistry options. We’re continuing to introduce new biosensors to bring label-free kinetic binding data to the benchtop of every researcher who would like to save time, cost, and resources in the drug discovery process.”

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay provide highly-sensitive kinetic characterization of small molecules and proteins in complex solutions such as DMSO, using just a 10 µL drop of sample, making the platform a cutting-edge orthogonal technique for drug discovery hit validation.

Read the full story at http://www.prweb.com/releases/Nanomedical_Diagnostics/NTA_Biosensor_Launch/prweb14515891.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Nanomedical Diagnostics Issued Key Patent for AGILE R100, a Graphene Biosensor for Drug Discovery
2. Nanomedical Diagnostics VP Production to Speak at Materials Research Society Spring Meeting
3. Nanomedical Diagnostics Announces Partnership with Rogue Valley Microdevices, Delivering World’s First Successful High-Volume Manufacturing for Graphene Biosensors
4. Nanomedical Diagnostics to Present Field Effect Biosensing for Fragment-Based Drug Discovery at SLAS 2017
5. Nanomedical Diagnostics CEO and CTO to Introduce Electronic Label-Free Assay Based on Field Effect Biosensing Technology at IDTechEx Show
6. Nanomedical Diagnostics launches a new graphene biosensor with unprecedented functionality for small molecule and protein analysis
7. Nanomedical Diagnostics Announces Scientific Advisory Board of Top Scientists and Medical Researchers
8. Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations
9. Co-Diagnostics, Inc. Announces Pricing of Initial Public Offering
10. Exact Diagnostics' Infectious Disease Calibrators for In Vitro Diagnostic (IVD) Use
11. Bio-Tech Firm PathSensors Launches High-Throughput Diagnostics for Plant Safety at 2017 American Phytopathological Society (APS) Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):